第1/2阶段卵巢癌研究的Rina-S50%的答复率;计划于2024年进行第3阶段试验。 50% response rate for Rina-S in Phase 1/2 ovarian cancer study; Phase 3 trial planned for 2024.

在1/ 2期研究中,Rinatabart sesutecan (Rina- S) 是一种针对叶酸受体- α的试验性抗体- 药物结合物,在晚期卵巢癌患者中显示出50%的客观反应率. Rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate targeting folate receptor-alpha, showed a 50% objective response rate in advanced ovarian cancer patients during a Phase 1/2 study. 对42名病人进行了检查,结果显示95%的病人抗白金素。 Conducted with 42 patients, the trial indicated that 95% were platinum-resistant. 为预计于2024年开始的第三阶段试验选择了Rina-S 120毫克/平方米。 Rina-S 120 mg/m² was selected for a Phase 3 trial expected to begin in 2024. 常见副作用包括贫血和恶心,但严重的不利事件很少。 Common side effects included anemia and nausea, but serious adverse events were minimal.